⌕
Arrowhead Pharmaceuticals · ARWR · Nasdaq
Tenet 33 · Weak
Compare
$42.99−2.76%At closeTenet 33 · Weak
$42.99−1.22 (−2.76%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Arrowhead Pharmaceuticals (ARWR) Earnings Forecast

Analysts expect Arrowhead Pharmaceuticals (ARWR) to lose $5.36 a share in FY27, the average of 11 estimates as of Nov 16, 2026.

Sources Analyst estimates EstimatesConsensus as of How we compute thisNot investment advice

4 figures withheld by our checks. Each blank figure names its reason.

FY27 consensus EPS
$−5.36
11 analysts
FY28 consensus EPS
$−3.68
7 analysts · low $−5.76, high $0.17
EPS revisions, 31 days
−10.4%
$−4.86 to $−5.36
Disagreement, FY27
$4.62
wide, $−7.46 to $−2.83

Consensus estimates only. Analysts' price forecasts and ratings are not licensed here.

Consensus as of Nov 16, 2026 · we check it nightly

Analysts expect Arrowhead Pharmaceuticals to earn $7.60 a share in FY31; 2 analysts publish an estimate for FY31.

Forward P/E · FY27E
—
$44.21 (as of close, Nov 16, 2026) ÷ $−5.36 consensus EPS
Coverage · FY27
11 · 9
EPS estimates · revenue estimates

Are estimates going up or down lately?

The FY27 EPS consensus is $−5.36, a loss that widened 13.6% in 90 days. Every figure compares one fiscal period at both ends.

EPS consensus, change over the last 90 days. One step per nightly change.

−38.1%−15.5%+7.1%FY27 −13.6%FY28 −30.9%Aug 18Nov 16
EPS30 days90 daysshown aboveSince Jul 6
FY2711 analysts▼ −10.4%$−4.86 to $−5.36▼ −13.6%$−4.72 to $−5.36▼ −37.4%$−3.90 to $−5.36
FY287 analysts23 of 30 days−30.9% so far23 of 90 days−30.9% so far▼ −30.9%$−2.81 to $−3.68
Dec '265 analysts▼ −6.6%$−1.37 to $−1.46▼ −3.1%$−1.41 to $−1.46▼ −3.1%$−1.41 to $−1.46
Mar '274 analysts23 of 30 days−6.0% so far23 of 90 days−6.0% so far▼ −6.0%$−1.30 to $−1.38

Contributors at both ends of the window: FY27 11 and 11. A change in the average can come from a new contributor as much as from a changed mind, so both counts stay in view.

Measured between two of our own nightly snapshots of one fiscal period, so a new fiscal year entering the view is never read as a revision. Never backfilled. A window still filling says how many days it holds; a blank one means our record is not that long yet.

If the Street is right, what does that imply for the share price?

Price as of close, Nov 16, 2026 · consensus as of Nov 16, 2026

EPS is a loss in the years the Street forecasts, and a multiple of a loss is not a price. So the sum switches to EBITDA, from FY30 on, which is the first year the consensus EBITDA is above zero, and waits for your multiple.

Consensus EBITDA · FY31
$1.9B
2 analysts · low $1.0B, high $3.1B · thin coverage
Multiple · five-year average P/E
40.9×
Average of the fiscal-year P/Es, FY19 to FY19.
×
Receipt · ARWR · FY31Nov 16, 2026
Implied, a share
$546

Range on the low and high estimate: $5 to $5.

$5 low$5 high
1.9B × 40.9, to the dollar
Drag the multipleShaded: where Arrowhead Pharmaceuticals' P/E sat at each fiscal year end, FY19 to FY19. Each dot is one year.
36×38×40×42×44×45×
5-yr avg 40.9×10-yr median 40.9×$546 a share

Each point on the line is a multiple, and the flag is the price it implies for FY31. Past multiples are context, not a guide to future ones.

This is multiplication, not a forecast. It assumes the market pays the multiple you chose and that the consensus is right. Both are often wrong.

Growth over a negative base is not meaningful. Consensus EPS is a loss in FY27, so there is neither a multiple of those earnings to pay nor a rate to grow from.

How much do analysts disagree?

For FY31, estimates run from $2.89 to $14.69 around an average of $7.60, drawn by 2 analysts.

FY27E11 analysts
$−7.46 to $−2.83 · $4.62 wide
FY28E7 analysts
$−5.76 to $0.17 · $5.93 wide
FY29E4 analysts
$−4.29 to $0.59 · $4.89 wide
FY30E1 analyst
$1.59 to $8.09 · $6.50 wide
FY31E2 analysts
$2.89 to $14.69 · $11.80 wide

The dashed line is FY26 filed $−5.11, on the GAAP basis.

A wide spread is disagreement, not risk; a narrow one is agreement, not accuracy. Later years are always wider because fewer people forecast them. Bars in amber rest on fewer than 15 analysts. The tick on each bar is the average. Spreads are shown in currency rather than as percentages, because a percentage of a number near zero overstates it.

Is next quarter a high bar or an easy one?

Analysts expect Arrowhead Pharmaceuticals to lose $1.46 a share in the December quarter, the average of 5 estimates. Results are expected by Feb 8, 2027. Last quarter, which ended in December, Arrowhead Pharmaceuticals earned $0.22 a share. Analysts had expected $0.04, so it came in 491.8% higher.

0
$0.22
$−1.46high $−1.18
low $−1.68
−761.8%crosses bases
Dec 2025 quarterfiled · GAAPDec 2026 quarterconsensus · Street basis · 5 analysts
Expected report
Feb 8, 2027
Expected by Feb 8. An estimate, not a date the company has set. Companies move it.
Revenue expected · December quarter
$45.0M
4 analysts, 21.7 to 65.0 in $M · 264.0 in the same quarter a year ago

The step from a filed quarter to a consensus crosses bases: the filed figure is the company's own GAAP number and the consensus is on the Street's basis. It is printed with both bases named, not as growth. Last quarter's comparison is measured against the last estimate we hold for that quarter rather than the one from the night before the report, because the nearest estimate we hold for it was recorded after the company had already reported. For the March quarter, analysts expect a loss of $1.38 a share.

Does Arrowhead Pharmaceuticals usually beat or miss?

So far we have checked 1 quarter: the one that ended in December 2025, when Arrowhead Pharmaceuticals earned $0.22 a share against the $0.04 analysts expected, 491.8% higher. We add a quarter to this record each time Arrowhead Pharmaceuticals reports. The next report is expected by Feb 8, 2027.

We started recording estimates on Jul 6, 2026, so quarters that reported before that date cannot be checked.

Our record, one quarter per report
Dec '23left out
Mar '24left out
Jun '24left out
Sep '24left out
Dec '24left out
Mar '25left out · basis
Jun '25left out
Sep '25left out
+491.8%
Dec '25reaction
−0.2%
Mar '26left out
Jun '26left out
Sep '26left out
reportsFeb 8
Dec '26
Checked so far
1 quarter
one more every report
Beat expectations
1 of 1
full details on the Earnings tab
Share price reaction
+1.4%
one session, timed to the December 2025 release
Typical gap vs estimate
Not yet
shown once 4 quarters are checked

Checked against the company's reported figure (GAAP) and the average estimate we recorded the night before its results release. Where analysts' number is on an adjusted basis, we leave the comparison out rather than force it. We started recording estimates for Arrowhead Pharmaceuticals on Jul 6, 2026, so earlier quarters cannot be checked, and we never fill them in after the fact. Dec '25 is drawn hollow: we hold no estimate for that quarter recorded strictly before the report, so it is scored against the last estimate we hold rather than the night-before one.

The Street expects sales to grow 80.3% in FY28. Consensus EPS is a loss at both ends of that step, so there is no EPS growth rate to take apart.

11 analysts publish an EPS estimate for FY27 and 9 publish revenue. Coverage thins with distance: 2 EPS estimates for FY31. Consensus figures are on the Street's basis and filed figures are GAAP; we label the gap, we do not explain it away.Show coverage by year and over timeHide the coverage chart
Analysts by fiscal year · outlined revenue, filled EPS. Amber marks a panel of fewer than 15.
911
FY27E
97
FY28E
74
FY29E
51
FY30E
22
FY31E
The FY27 panel held 10 analysts when our record of it began on Jul 6, 2026 and holds 11 tonight.

The full consensus, year by year

Consensus as of Nov 16, 2026 · filed figures as reported
Revenue · $Bfiled · consensus average · band = low to high
−0.32.45.0historyStreet forecastFY23FY26FY31E

Coverage thins with distance: 9 revenue estimates for FY27, 2 for FY31.

Diluted EPS · $filed · consensus average · band = low to high
−8.783.3915.57historyStreet forecastFY23FY26FY31E

Out-year bands widen as fewer analysts publish: 11 EPS estimates for FY27, 2 for FY31.

Fiscal yearRevenue $BYoYEPS $YoYEBITDA $BNet inc. $BShares BAnalysts rev · EPSFwd P/E
FY26Filed0.5—−5.11————as filedn/m
FY27E0.30.1 to 0.5▼32.1%a−5.36−7.46 to −2.83n/ca−0.7−0.80.159 · 11—
FY28E0.60.3 to 0.8▲80.3%−3.68−5.76 to 0.17n/cb−0.3−0.40.129 · 7—
FY29E1.00.7 to 1.5▲80.4%−2.37−4.29 to 0.59n/cb−0.0−0.30.117 · 4—
FY30E2.01.1 to 3.5▲103.7%4.191.59 to 8.09n/cb1.10.60.145 · 110.6×
FY31E2.81.5 to 4.8n/cb7.602.89 to 14.69n/cb1.91.10.142 · 25.8×

Average estimate with low to high beneath. Amber counts mark thin coverage and thin rows carry an amber rule. Shares = consensus net income ÷ consensus EPS, a direction rather than a decimal. The filed row's last column is today's price over that year's filed EPS, the one trailing multiple in that column. a This step crosses the seam: last year is a filed GAAP actual and this year is a consensus estimate, so the two are not prepared on one basis. b More than a third of the analyst panel changed between these two years, so the difference of the two averages measures the panel rather than the forecast.

These are consensus estimates: what analysts expect the business to earn, not where they think the stock trades. Coverage thins and the low to high band widens in the out-years. Context, not advice.

Analysts' price forecasts and grades are not licensed here. This page shows forward consensus estimates only: 11 EPS estimates for FY27, 9 for revenue. Not investment advice.

What do analysts expect Arrowhead Pharmaceuticals to earn in FY27?

Analysts expect Arrowhead Pharmaceuticals to lose $5.36 a share in FY27, the average of 11 estimates as of Nov 16, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.